Applied Therapeutics (APLT)
(Delayed Data from NSDQ)
$0.48 USD
+0.01 (1.17%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.48 0.00 (0.95%) 5:00 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
APLT 0.48 +0.01(1.17%)
Will APLT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APLT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLT
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates
APLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?
Company News for Dec 2, 2024
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More
Other News for APLT
Applied Therapeutics Announces New Chief Medical Officer
APLT Announces Key Executive Promotions | APLT Stock News
Applied Therapeutics Announces Key Leadership Appointments | APLT Stock News
Applied Therapeutics CMO Riccardo Perfetti to depart, Evan Bailey to succeed
Applied Therapeutics CMO Riccardo Perfetti to depart, Evan Bailey to succeed